Key facts
- PhosPrint’s last known valuation is $5.8M (Dec 2025).
- It has raised $590K; the latest was Later Stage VC ($580K) in Dec 2025.
- Notable investors include European Innovation Council, Corallia Ventures, Lars Rasmussen, StartSmart South Eastern Europe.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for PhosPrint
- ·The full record, as it builds
Funding rounds
No funding rounds for PhosPrint are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PhosPrint
Developer of laser bioprinting systems and specialized regenerative medicine applications designed for tissue regeneration. The company specializes in laser bioprinting systems and regenerative medicine, offering on-site cell printing during surgery and it offers healthcare technology products that aim to offer laser bioprinting, biotechnology research and more, enabling researchers and experimental surgery units to access the tools and procedures to battle diseases and medical conditions.
- Sector
- Healthcare
- HQ
- Athens, Greece
- Founded
- 2019
- Employees
- 9
- Website
- phosprint.eu/
- Ownership
- Privately Held (backing)
PhosPrint doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhosPrint shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhosPrint in its N-PORT filings yet. We sweep new filings monthly.